OAG
UTHR icon

Oakmont Advisory Group’s United Therapeutics UTHR Stock Holding History

Oakmont Advisory Group’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$379K Buy
700
+20
+3% +$11.3K 0.32% 81
2026
Q1 		$403K Buy
680
+16
+2% +$7.97K 0.41% 66
2025
Q4 		$324K Buy
+664
New +$309K 0.35% 89

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Oakmont Advisory Group's UTHR Position: Q2 2026 in Review

Oakmont Advisory Group increased its United Therapeutics (UTHR) stake by 2.9% in Q2 2026, buying an estimated $11.3K and bringing the position to 700 shares worth $379K. The position accounts for 0.32% of the portfolio, ranked #81.

Oakmont Advisory Group first reported a position in UTHR in Q4 2025 and has held it in 3 quarters since. The position peaked at $403K in Q1 2026. 874 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Oakmont Advisory Group held 700 shares of United Therapeutics worth $379K as of Q2 2026.
  • Oakmont Advisory Group bought 20 United Therapeutics shares in Q2 2026, an estimated $11.3K.
  • United Therapeutics made up 0.32% of Oakmont Advisory Group's portfolio in Q2 2026, its #81 holding.
  • Oakmont Advisory Group first reported a position in United Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Oakmont Advisory Group's United Therapeutics position peaked at $403K in Q1 2026.
  • 874 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Oakmont Advisory Group's 13F filing for Q2 2026, filed 3 Aug 2026.